DB05218ExperimentalProtein Based Therapies
PN0621 is an anti-TNF, domain antibody (dAb) based therapeutic. It targets tumour necrosis factor (TNF) to treat auto-immune inflammatory diseases such as rheumatoid arthritis. It is being developed by Peptech.
- Mechanism
- Curator reviewed
Auto-immune diseases are indicated where an individual's immune system mistakenly attacks the body's own tissues. PN0621 works by blocking the action of TNF (tumour necrosis factor) which is involved in this attack.
- Primary indication
- Intended for the treatment of auto-immune diseases such as rheumatoid arthritis, psoriasis and Crohn's disease.Curator reviewed
- Code names
- PN0621
Resolves to
Targets
What you can answer from here — as of April 02, 2025
1Protein targetEach mapped to UniProt, with action and pharmacological actionListed above
Which drugs share a target with PN0621, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account